Current Landscape and Future Opportunities in the Global

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Nov 10, 2015 at 10:00 PM

Current Landscape and Future Opportunities in the Global Protein Expression Systems Market 2015

Dublin, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/jrms47/protein ) has announced the addition of the "Protein Expression Systems Market: Current Landscape and Future Opportunities" report to their offering. The Protein Expression Systems Market: Current Landscape and Future Opportunities report provides an extensive study of the various expression systems commercially available for the purpose of expressing the desired proteins. Selecting an effective and reliable expression system is one of the pre-requisites for pharma companies before they start proof of concept studies for biological molecules. It is well known that a particular expression system is not suitable to express every kind of protein. As such, there are several different types of platforms available to meet the growing demand. With an extensive pipeline of biologic drugs, protein expression systems are likely to continue to garner significant attention from the biopharmaceutical industry. The report covers various aspects such as key features of these systems, associated products, licensing and services portfolio. We have also covered specific details on CMOs manufacturing biopharmaceutical products highlighting their capabilities, geographical location, scale of operation, type of biologics being manufactured and expression systems being used. In addition, the report highlights the future growth prospects with respect to manufacturing biological molecules. The report has analyzed the overall biologics pipeline and provided specific details on some important classes such as antibody drug conjugates (ADCs) and bispecific antibodies. In addition, the emerging opportunity presented by the ongoing development of biosimilars has been highlighted. For the purposes of the study, important stakeholders were interviewed to solicit their opinions around the upcoming opportunities and challenges which must be considered for a more inclusive growth. Examples of companies interviewed include Research Corporation Technologies, iBio and Jena Bioscience. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Market Overview 5. Expression Systems: Key Features and Products 6. Company Profiles 7. CMO Services 8. Opportunity Analysis 9. SWOT Analysis 10. Interview Transcripts 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - 3P Biopharmaceuticals - 5 PRIME - AAIPharma Services - AbbVie - AbGenomics - Abnova - AdAlta - ADC Therapeutics - Aeras - Affinicon - Affinity Life Sciences - Agilent Technologies - Ajinomoto Althea - Aldevron - Allele Biotechnology - Alliance Medical Products (Siegfried) - Alpax Pharmaceuticals - Ambrx - AMEGA Biotech - AMYRA Biotech - Apotex Fermentation - Aragen Bioscience - Artes Biotechnology - Asahi Glass Co. - Astellas - AthenaES - AutekBio - Avecia - Avesta Biotherapeutics and Research - Avid Bioservices - Batavia Bioservices - Bavarian Nordic - Baxter BioPharma Solutions - Bayer Healthcare - BD Biosciences - Bharat Biotech - BIBITEC - Binex Co. - Bio Elpida - BioCision - Bio-Concept - BioConnection - BioConvergence - BioGenomics - BioGrammatics - Bioinformatics - BioIngenium - BioMARC - Biomay - BIOMEVA - Bioneer - Frederick National Laboratory for Cancer Research (FNLCR) - BioPharmaceuticals Australia - Bio-Rad Laboratories - BioReliance - BioSavita - BioSynergy - Biotechnique - Biotechpharma - Biotest - BioVectra - Biovest International - Biovian - Biovolutions - BioXcellence (Boehringer Ingelheim) - Bristol Myers Squibb - BroadOak Capital Partners - Cantab Biopharmaceuticals - Catalent - Catalyst biosciences - Cellca - Celldex Therapeutics - CellFree Sciences - Celgene - Celonic - Center for Biocatalysis and Bioprocessing, The University of Iowa - Cerbios-Pharma - CEVEC Pharmaceuticals - ChemPartner - Cilian - Clontech (a Takara Bio Company) - CMC Biologics - Cobra Biologics - Cognate BioServices - Concord Biotech - Cook Pharmica - Creative Biolabs - Crucell - Cytovance Biologics - Dalton Pharma Services - Development Center for Biotechnology, Taiwan - DisperSol technologies - DM BIO DONG-A meiji - Dow Pharma - Dyadic International - Emergent BioSolutions - Enteris BioPharma - Esperance Pharmaceuticals - EUCODIS Bioscience - Eurogentec - Florida Biologix - FormATECH - Formation Biologics - FUJIFILM Diosynth Biotechnologies - Fujirebio Europe - Gala Biotech (Catalent subsidiary) - GeneCopoeia - Geneva Biotech - Genhelix (mAbxience group) - Genmab - GlaxoSmithKline Biopharmaceuticals - Glide Pharma - Glycotope Group - Gold Standard Diagnostics - Goodwin Biotechnology - Grand River Aseptic Manufacturing - GREENOVATION - GTP Technology - HALIX - Hisun Pharmaceuticals USA - Hong Kong Institute of Biotechnology - Hospira One 2 One - iBIO - IDT Biologika - Inno Biologics - Innovent Biologics - Intas Pharmaceuticals - Integrity Bio - Intrexon - Irvine Pharmaceutical Services - Jena Bioscience - Jenrin Discovery - KABS Pharmaceutic Services - Kairos Therapeutics - KBI BioPharma - Kemwell Biopharma - Kentucky BioProcessing - Lampire Biological Laboratories - Leinco Technologies - LFB Biomanufacturing - Life Technologies - LifeSensors - Lonza - Lucigen - Lyophilization Services of New England. - Mabion - Maine Biotechnology Services - MassBiologics - MBI International - Medicago - Memorial Sloan-Kettering Cancer centre - Menarini Biotech - Merck KGaA - Merck Millipore - Merck Serono - Meridian Life Science - Miltenyi Biotec - MoBiTec - Mycenax Biotech - Neuland Laboratories - New England Biolabs - Nextar Chempharma Solutions - Norwegian Institute of Public Health - Nova Laboratories - Novasep - Novozymes - OctoPlus - Omnia Biologics - Orflo Technologies - OsoBio (AMRI) - Oxford Expression Technologies - PacificGMP - PATH - Paragon Bioservices - Patheon (unit of DPx Holdings) - Pfizer CentreSource - PharmaSynth - Pharmedartis - Phyton Biotech - Piramal Pharma Solutions - Plant BioScience - Plasmid Factory - Polymun Scientific - Premas Biotech - ProBioGen - ProteoNic - Progenitor Cell Therapy - ProMab Biotechnologies - Promega Corporation - Protalix Biotherapeutics - Provantage Biodevelopment Center - PX'Therapeutics - PYRAMID Laboratories - QuaDPharma - Reliance Life Sciences - Rentschler Biotechnologie - Research Corporation Technologies - Rhein Biotech - Richter-Helm BioTec - RiNA - SAFC - Samsung BioLogics - Sandoz - Sanofi Pasteur - Sanofi CEPiA - Sanquin Pharmaceutical Services - Scarab Genomics - Scil Proteins - Shasun - SICOR Biotech (Teva) - Sigma-Aldrich Corporation - Sinocelltech - Statens Serum Institut - Strides Arcolab - Sutro Biopharma - Symbiosis Pharmaceutical Services - SynCo Bio Partners - Syngene (Subsidiary of Biocon) - Synthon - Sypharma - Tetragenetics - Teva Pharmaceuticals - Therapure Biopharma - Thermo Fisher Scientific - Toyobo Biologics - Trenzyme - University of California, San Francisco (UCSF) - University of Nebraska - Valneva - Vetter Pharma International - VGXI - Vibalogics - Vista Biologicals Corp. - Vivalis SA - VTU Technology - Wacker Biotech - Waisman Biomanufacturing - Wockhardt - WuXi AppTec - Xbrane Bioscience - Xcelience - Zhejiang Medicine Co. - Zymeworks For more information visit http://www.researchandmarkets.com/research/jrms47/protein

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Proteomics

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Millrose Faces Class Action: Blame Game in Motion

Millrose Properties: A Realty Ruckus Unfolding Sometimes, in the world of stocks, it feels like you're two steps ahead of the scam or already knee-deep in trouble. Millrose Properties, Inc. struck a rather sour chord recently with an 8.53% stock drop, leaving investors feeling the burn. Here's the juice: a securities fraud class action is in motion, and if you're holding...

St. Croix Financial Hub: Game Changer or Fluff?

You know, sometimes it feels like the financial world gets more tangled than a fishing line on a windy beach. This latest spiel coming out of St. Croix with all its big names and lofty promises—Governor Bryan’s 3rd Wall Street Financial District Hub Initiative—seems like one of those, but maybe it’s got more meat than hype. Half the pitch sounds like your typical...

Cesar Alvarez Honored with Prestigious Miami Award

Cesar Alvarez's Legacy Honored in Miami The Greater Miami Chamber of Commerce's 2026 Sand in My Shoes® Award has found its latest recipient in Cesar L. Alvarez, the Senior Chairman of Greenberg Traurig, P.A. It wasn't just a ceremony—this was a gathering of more than 800 of Miami's business and community power players on October 15, 2026. And man, did it shine a bright...

CTG Data Breach Sparks Class Action Investigation

CTG Faces Scrutiny Over Recent Data Breach Ah, the thrills and spills of the digital age—yet another company stumbling headfirst into a data breach mess. This time, it’s Computer Task Group (CTG) taking center stage, with its IT systems compromised and personal info slipping through the cracks. On September 26, 2026, an unwelcome guest rooted around their network,...

Lazard's Q3 2026: Surging Revenue, Waning Net Income

Breaking Down the Numbers Lazard just dropped its Q3 2026 earnings report, and you can smell both optimism and caution in the air. Sure, $814 million in net revenue isn’t anything to sneeze at, especially when it’s a neat 9% jump from last year’s $748 million. Adjusted figures were a whisker away at $805 million. But dig deeper, and things get a tad less rosy—net...

Mario Lopez: Homegrown Star Hosts Birthday Tequila Bash

Not every day do you get a celeb hitting their home turf just to throwback with fans, but that's Mario Lopez for you. Coming right into San Diego for his birthday month, Lopez isn't just sipping tequila—he’s signing it. Swing by Old Town Tequila and Keg N Bottle this October 24 if you want a bottle of Casa México Tequila adorned with a little star power. Sips,...

New Blood Joins Board: A Power Move for Bank of America

A Fresh Breeze in the Boardroom Bank of America isn't sitting still. They're shaking things up by bringing in Jim Fitterling and Bill Thomas. Now, why’s that a big deal for those watching NYSE:BAC? Well, these guys pack heavy resumes, and their experience could steer the ship with precision across turbulent financial waters. The Minds Behind the Names Let's chew the fat...

Side Bolsters Art Division with Roboto Acquisition

Breaking Into China's Game Art Market The gaming industry's latest buzz centers around Side's acquisition of Roboto Entertainment, a boutique art studio known for crafting immersive game environments. This isn't just another headline grab—this move puts Side smack dab in the heart of China's burgeoning game market with a fresh Chengdu base. Expansion With Strategic...

McLean Guide: Turning Culture Data into Real Action

Unlocking the Potential of Culture Measurement In the corporate jungle, culture is like oxygen. You don’t see it, but you sure as heck feel it when it’s missing or toxic. McLean & Company just dropped a new guide that promises to map out the invisible by measuring organizational culture. Now, you might say, 'Cultural alignment sounds like consultant mumbo-jumbo.' But...

Genedata's AI Push: A Biotech Game-Changer?

A Glimpse into Genedata's Bold AI Integration So, here's a heck of an ambitious move in the biotech sphere with Genedata dropping the news about their integration of NVIDIA's BioNeMo AI models into their R&D workflows. These folks at Genedata are really riding the tech wave, offering up the new RFD4-Proteina release in what they call 'binder design' for biologics...